| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H11N3O4S2 |
| Molecular Weight | 337.374 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(C(=O)NC2=NC=CS2)=C(O)C3=C(C=CC=C3)S1(=O)=O
InChI
InChIKey=SYCHUQUJURZQMO-UHFFFAOYSA-N
InChI=1S/C13H11N3O4S2/c1-16-10(12(18)15-13-14-6-7-21-13)11(17)8-4-2-3-5-9(8)22(16,19)20/h2-7,17H,1H3,(H,14,15,18)
Sudoxicam is a nonsteroidal anti-inflammatory drug patented by American multinational pharmaceutical corporation Pfizer for the treatment of thrombosis. Sudoxicam strongly inhibited aggregation of rabbit, dog, and human platelets caused by collagen, but not by ADP. Sudoxicam inhibited the secondary phase of the biphasic response of guinea pig platelets to ADP and suppressed the release of ADP from human platelets caused by collagen. Sudoxicam shows superior anti-inflammatory activity compare to indomethacin in rat paw edema model. In clinical trials, sudoxicam was associated with several cases of severe hepatotoxicity that led to its discontinuation.
Originator
Approval Year
ACTIVE MOIETY
